Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases. This issue of the Urologic Clinics focuses on NMIBC and includes articles on periopertive chemotherapy, office fulguration, TURBT, surveillance strategies, and radiation therapy in type-1 tumors.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. CME Accreditation Page and Author Disclosure - p. 5 6. Forthcoming Issues - p. 6 7. Foreword - p. 7 8. Non-Muscle Invasive Bladder Cancer - p. 8 9. NMIBC Risk Calculators - p. 9 10. Urinary Markers/Cytology - p. 17 11. Office-based Bladder Tumor Fulguration and Surveillance - p. 23 12. Perioperative Chemotherapy - p. 28 13. Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects - p. 35 14. Strategies for Optimizing Bacillus Calmette-Guérin - p. 45 15. New Agents for Bacillus Calmette-Guérin–Refractory Bladder Cancer - p. 52 16. Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma - p. 63 17. The Conundrum of Prostatic Urethral Involvement - p. 75 18. The Costs of Non-Muscle Invasive Bladder Cancer - p. 83 19. New Imaging Techniques for Non-Muscle Invasive Bladder Cancer - p. 90 20. Diagnostically Challenging Cases - p. 97 21. Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer - p. 105 22. Optimal Risk-Adapted Surveillance Strategies for NMIBC, Including Upper Tract Imaging - p. 113 23. Index - p. 119
No hay muestra disponible
No hay ficha técnica disponible
Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases. This issue of the Urologic Clinics focuses on NMIBC and includes articles on periopertive chemotherapy, office fulguration, TURBT, surveillance strategies, and radiation therapy in type-1 tumors.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. CME Accreditation Page and Author Disclosure - p. 5 6. Forthcoming Issues - p. 6 7. Foreword - p. 7 8. Non-Muscle Invasive Bladder Cancer - p. 8 9. NMIBC Risk Calculators - p. 9 10. Urinary Markers/Cytology - p. 17 11. Office-based Bladder Tumor Fulguration and Surveillance - p. 23 12. Perioperative Chemotherapy - p. 28 13. Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects - p. 35 14. Strategies for Optimizing Bacillus Calmette-Guérin - p. 45 15. New Agents for Bacillus Calmette-Guérin–Refractory Bladder Cancer - p. 52 16. Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma - p. 63 17. The Conundrum of Prostatic Urethral Involvement - p. 75 18. The Costs of Non-Muscle Invasive Bladder Cancer - p. 83 19. New Imaging Techniques for Non-Muscle Invasive Bladder Cancer - p. 90 20. Diagnostically Challenging Cases - p. 97 21. Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer - p. 105 22. Optimal Risk-Adapted Surveillance Strategies for NMIBC, Including Upper Tract Imaging - p. 113 23. Index - p. 119
No hay muestra disponible
No hay ficha técnica disponible
